Related references
Note: Only part of the references are listed.Efficacy of gemcitabine plus doxorubicin (Gem plus Dox) in patients with renal medullary carcinoma (RMC).
Nathaniel Wilson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
Andrew J. Wiele et al.
CANCERS (2021)
Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma
Pavlos Msaouel et al.
CANCER CELL (2020)
Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma
Pavlos Msaouel et al.
CLINICAL GENITOURINARY CANCER (2019)
Renal Medullary Carcinoma
Alexis Elliott et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors
Alessandro Carugo et al.
CANCER CELL (2019)
Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study
Amishi Y. Shah et al.
BJU INTERNATIONAL (2017)
Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer
Giannicola Genovese et al.
NATURE (2017)
Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases
Marcus A. Carden et al.
PEDIATRIC BLOOD & CANCER (2017)
Renal medullary carcinoma: A national analysis of 159 patients
Brian Ezekian et al.
PEDIATRIC BLOOD & CANCER (2017)
Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
Kathryn E. Beckermann et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Renal Medullary Carcinoma: Establishing Standards in Practice
Kathryn E. Beckermann et al.
JOURNAL OF ONCOLOGY PRACTICE (2017)
Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes
Maria I. Carlo et al.
CLINICAL GENITOURINARY CANCER (2017)
Therapeutic approach guided by genetic alteration: Use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression
Jacob S. Lipkin et al.
CANCER BIOLOGY & THERAPY (2015)
Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature
Roberto Iacovelli et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2015)
Renal medullary carcinoma and sickle cell trait: A systematic review
Ofelia Alvarez et al.
PEDIATRIC BLOOD & CANCER (2015)
Active combination of platins/paclitaxel/gemcitabine/bortezomib in a child with metastatic renal medullary carcinoma (RMC)
M. M. Al-Rahawan et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy
Edward M. Schaeffer et al.
BJU INTERNATIONAL (2010)
Complete Response to Carboplatin, Gemcitabine, and Paclitaxel in a Patient With Advanced Metastatic Renal Medullary Carcinoma
Alexandra Walsh et al.
PEDIATRIC BLOOD & CANCER (2010)
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors
E. Claire Dees et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Renal medullary carcinoma: The Bronx experience
A. Ari Hakimi et al.
UROLOGY (2007)
Phase II trial of bortezomib for patients with advanced renal cell carcinoma
GV Kondagunta et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
